The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland DOI Creative Commons
Alekh Thapa, Anna Cowell, Adam Peters

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: June 12, 2023

Abstract Objectives The Scottish Medical Consortium recently approved first-line pembrolizumab monotherapy or in combination with chemotherapy for head and neck squamous cell carcinoma (HNSCC) the palliative setting, contrasting decision made by National Institute Health Care Excellence who alone England Wales. We aimed to provide real-world performance data pembrolizumab-containing treatments setting Scotland. Materials Methods analysed electronic records of patients initiated treatment between 01/03/2020–30/09/2021. Outcomes included overall survival (OS), progression-free (PFS), duration response (DOR), disease control rate (DCR). Data were compared KEYNOTE-048 study clinical factors evaluated association survival. Results Our cohort 91 (median follow-up 10.8 months). Patient characteristics similar though our had a higher proportion newly diagnosed, non-metastatic disease. For receiving (n=76), 12-month 24-month OS was 45% 27%, respectively. pembrolizumab-chemotherapy (n=15), 60% (24-month not yet been reached). Experiencing ≥1 irAE (versus no irAEs), any grade, associated favourable PFS both univariable log-rank analysis 17.4 months versus 8.6 months, respectively, P=0.0033; median 10.9 3.0 P<0.0001) multivariable (Cox proportional hazards regression: HR: 0.31, P=0.0009; 0.17, P<0.0001). Conclusion support findings value options. Additionally, show irAEs as reported routine records, are better outcomes this patient group, adding growing body evidence showing generally positive marker PD-L1 inhibitor response.

Language: Английский

Top tips for treating patients with a history of head and neck cancer DOI

T Mehmet,

Alexandra J. Murray,

C R Mackie

et al.

BDJ, Journal Year: 2024, Volume and Issue: 237(6), P. 438 - 441

Published: Sept. 27, 2024

Language: Английский

Citations

0
The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland DOI Creative Commons
Alekh Thapa, Anna Cowell, Adam Peters

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: June 12, 2023

Abstract Objectives The Scottish Medical Consortium recently approved first-line pembrolizumab monotherapy or in combination with chemotherapy for head and neck squamous cell carcinoma (HNSCC) the palliative setting, contrasting decision made by National Institute Health Care Excellence who alone England Wales. We aimed to provide real-world performance data pembrolizumab-containing treatments setting Scotland. Materials Methods analysed electronic records of patients initiated treatment between 01/03/2020–30/09/2021. Outcomes included overall survival (OS), progression-free (PFS), duration response (DOR), disease control rate (DCR). Data were compared KEYNOTE-048 study clinical factors evaluated association survival. Results Our cohort 91 (median follow-up 10.8 months). Patient characteristics similar though our had a higher proportion newly diagnosed, non-metastatic disease. For receiving (n=76), 12-month 24-month OS was 45% 27%, respectively. pembrolizumab-chemotherapy (n=15), 60% (24-month not yet been reached). Experiencing ≥1 irAE (versus no irAEs), any grade, associated favourable PFS both univariable log-rank analysis 17.4 months versus 8.6 months, respectively, P=0.0033; median 10.9 3.0 P<0.0001) multivariable (Cox proportional hazards regression: HR: 0.31, P=0.0009; 0.17, P<0.0001). Conclusion support findings value options. Additionally, show irAEs as reported routine records, are better outcomes this patient group, adding growing body evidence showing generally positive marker PD-L1 inhibitor response.

Language: Английский

Citations

0